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Abstract
Introduction: The aim of the present study was to investigate the association between cardiovascular risk factors and 
endothelial dysfunction in patients with mixed connective tissue disease (MCTD) and to determine which biomarkers 
are associated with atherosclerotic complications, such as cardiovascular disease.
Methods: Fifty MCTD patients and 38 healthy age-matched and sex-matched controls were enrolled in this study. In 
order to describe endothelial dysfunction, we assessed flow-mediated dilation (FMD), nitrate-mediated dilation (NMD) 
and carotid artery intima-media thickness (IMT). We investigated FMD of the brachial artery after reactive hyperemia 
and NMD after sublingual nitroglycerin administration, while the IMT of the common carotid artery was determined by 
ultrasound. Anti-U1 ribonucleoprotein (anti-U1RNP) antibodies, anti-cardiolipin (anti-CL) antibodies, anti-endothelial 
cell antibody (AECA) and endothelial cell markers, such as soluble thrombomodulin (TM) and von Willebrand factor 
antigen (vWFAg), were assessed.
Results: The endothelium-dependent vasodilation (FMD) was significantly impaired in patients with MCTD, as 
compared with controls (%FMD: 4.7 ± 4.2% vs. 8.7 ± 5.0%; P < 0.001), while the percentage NMD did not differ (%NMD: 
14.3 ± 6.6% vs. 17.1 ± 6.7%; P = 0.073). Mean carotid IMT values were higher in patients than in controls (IMT: MCTD, 
0.64 ± 0.13 mm vs. controls, 0.53 ± 0.14 mm; P < 0.001). FMD negatively correlated with disease duration, the levels of 
apolipoprotein A1, the paraoxonase-1 activity, and systolic blood pressure in MCTD patients. The percentage FMD was 
significantly lower in MCTD patients with cardiovascular diseases (CVD), than in those without CVD (%FMD: 3.5 ± 2.9 vs. 
5.8 ± 4.8, P < 0.0002), while percentage NMD did not differ between patients with and without CVDs. Serum levels of 
autoantibodies (anti-U1RNP, AECA and anti-CL) were significantly higher in MCTD patients and differed between MCTD 
patients with and without CVD. Endothelial cell markers such as soluble TM (12.2 ± 8.1 ng/ml vs. 3.2 ± 1.3 ng/ml; P < 
0.001) and vWFAg (224.1 ± 115% vs. 89.4 ± 27.1%, P < 0.001) were the highest in MCTD patients with CVD.
Conclusions: FMD is a reliable sensitive marker of endothelial cell dysfunction in MCTD. Beside the traditional risk 
factors, anti-U1RNP, AECA and anti-CL antibodies may be important not only in the pathogenesis of MCTD but in the 
induction of endothelial cell activation, and may play crucial roles in the development of early atherosclerosis in MCTD.
Introduction
Systemic autoimmune diseases, such as systemic lupus
erythematosus (SLE), rheumatoid arthritis or systemic
sclerosis, are chronic inflammatory disorders - signified
by complex interactions amongst traditional and nontra-
ditional disease-related phenomena, including inflamma-
tion, dyslipidemia, thrombotic events, and humoral
autoimmune processes [1-3]. Mixed connective tissue
disease (MCTD) is also a chronic inflammatory systemic
autoimmune disease, characterized by high titers of anti-
U1 ribonucleoprotein (anti-U1 RNP) antibodies [4-7].
The frank tissue inflammation and proliferating vascu-
lar arteriopathy is a specific feature of MCTD. Prolifera-
tive vasculopathy involves the small and large arteries in
* Correspondence: edit.bodolay@gmail.com
1 3rd Department of Medicine, Medical and Health Science Center, University 
of Debrecen, Moricz Zs. Str. 22, Debrecen 4032, Hungary
Full list of author information is available at the end of the articleSoltesz et al. Arthritis Research & Therapy 2010, 12:R78
http://arthritis-research.com/content/12/3/R78
Page 2 of 11
various organs. The lung is the most frequent predilec-
tion place of the vascular damage, however, and may
eventually lead to pulmonary arterial hypertension (PAH)
[8]. Our group and others found that PAH might be asso-
ciated with coexistent antiphospholipid and anti-
endothelial cell antibodies (AECAs) [9,10]. In our previ-
ous study we found that AECA provokes the surface
expression of E-selectin and the activation of endothelial
cells [11]. In sera of patients with PAH, high concentra-
tions of thrombomodulin (TM) and von Willebrand fac-
tor antigen (vWFAg) secreted from Weibel-Palade bodies
imply an activated state of the endothelial cells. TM - an
endothelial high-affinity receptor for thrombin - has an
anticoagulant effect, activating the protein C system [12].
Soluble TM can be measured in peripheral blood, and an
elevated level of soluble TM is a marker of endothelial
injury.
Previously we described high levels of total serum cho-
lesterol and reduced paraoxonase-1 (PON1) concentra-
tions and activity in patients'sera [13]. PON1 has an
antioxidant function, and it is a key factor in atheroscle-
rotic events [13].
These data suggest that patients with MCTD have the
traditional risk factors for the early development of ath-
erosclerosis. The connection between endothelial cell
damage and atherosclerosis in MCTD, however, has not
been described previously.
Endothelial dysfunction is both an early marker of vas-
cular diseases and a facilitating factor in the development
of atherosclerosis [14-16]. Flow-mediated dilatation
(FMD) of the brachial artery is a reliable and reproducible
non-invasive tool to evaluate endothelial function [17-
19]. The administration of sublingual nitrates is a good
test to examine the vasodilatatory effect of an exogenous
source of nitric oxide. The increase in carotid intima-
media thickness (IMT) is a useful marker of systemic sub-
clinical atherosclerosis and a strong predictor of subse-
quent myocardial infarction and stroke [20-22].
Since endothelial dysfunction represents an early stage
of atherogenesis, the aim of this study was to determine
whether impaired FMD amongst other biomarkers of
endothelial dysfunction, is characteristic of patients with
MCTD.
We aimed to determine which factors are associated
with cardiovascular events in MCTD. We also investi-
gated the endothelial cell functions, especially FMD,
together with the circulating endothelial cell markers,
soluble TM and vWFAg, reflecting the state of activation/
damage of the endothelium. Finally, we investigated the
relationship between peripheral endothelial dysfunction
and carotid IMT.
Materials and methods
Patients
Fifty women with MCTD, treated and followed-up at the
3rd Department of Internal Medicine, University of
Debrecen, were enrolled in the present study. Of these, 23
women (46%) had a history of cardiovascular diseases
(CVDs). CVD was diagnosed if: the patient had acute
myocardial infarction, or had ECG signs of myocardial
infarction, recorded semi-annually; the coronary disease
was treated with coronary bypass operation or angio-
plasty; or angina was verified by angiography and/or the
ischemic alterations were verified by a non-invasive test
or tissue Doppler's examination. Twenty-seven female
MCTD patients without CVD were included and denoted
as the MCTD/CVD-negative group.
All patients fulfilled the criteria for MCTD according to
Alarcon-Segovia and Villarreal [23]. Clinical disease
activity was assessed by the systemic lupus activity mea-
sure (SLAM) retrospectively from the patients' reports
[24,25]. A SLAM value >6 was considered high disease
activity.
MCTD patients were followed-up every 4 months at
the outpatient clinic. Diagnostic procedures for MCTD
included X-ray scan, lung function tests, electromyogra-
phy and electroneurography. Esophageal involvement
was detected by radionuclid esophageal transit scintigra-
phy and radiographic passage using gastrographin, or
barium. Myositis was confirmed by muscle biopsy and/or
electromyogram and creatinine kinase elevation. Ray-
naud's phenomenon was assessed by a positive color
chart or cold test, and morphological abnormalities were
assessed by nailfold capillary microscopy (Nikon Corp.,
Vienna, Austria).
Abnormal findings were assessed, as earlier described
by Maricq [26]. Abnormal findings were as follows: num-
ber of loops in a linear 1 mm width, enlargement of capil-
lary loops, or presence of bushy capillaries and avascular
areas. Avascularization was assessed by methods
described by Lee and colleagues [27]. The scleroderma
pattern was characterized by nailfold microhemorrhages,
enlarged loops, and avascular areas.
In laboratory analyses, we assessed the erythrocyte sed-
imentation rate (ESR), high-sensitivity C-reactive protein
(hs-CRP), the routine blood count, and the renal and liver
function; urine analysis was also performed. Traditional
risk factors for cardiovascular disease such as age, body
mass index (BMI), fasting plasma glucose, plasma lipid
levels, as well as blood pressure were recorded.
Thirty-eight age-matched and BMI-matched female
control subjects were also enrolled in the study. Exclusion
criteria included known CVD, diabetes mellitus, obesity
(BMI >30), and infection. Patients and controls had not
consumed alcohol or taken vasoactive drugs within theSoltesz et al. Arthritis Research & Therapy 2010, 12:R78
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past 24 hours. No patients received lipid-lowering thera-
pies 48 hours before the study.
Cumulative lifetime corticosteroid dose (prednisone
equivalent/grams) was calculated from hospital records.
Twenty-two out of 50 patients with MCTD received non-
steroidal anti-inflammatory drugs, 10 patients had the
combination of corticosteroids (CS) and salazopyrine,
and 11 patients received a combination therapy of CS and
methotrexate, while seven patients received CS therapy
alone.
The protocol was in full compliance with the Good
Clinical Practices, the Declaration of Helsinki, and the
guidelines of the Medical and Health Science Centre of
the University of Debrecen. The protocol has been
approved by the institutional ethics committee (Regional
and Institutional Ethics Committee, Medical and Health
Science Centre, University of Debrecen). Written
informed consent was obtained from all patients and
healthy controls.
Immunoserological investigations
The detection of antinuclear antibodies on the HEp2 cell
line was carried out by indirect immunofluorescence.
The serum concentrations of autoantibodies were ana-
lyzed by ELISA according to the manufacturer's instruc-
tions: anti-Sjögren syndrome-associated antigen A
antibodies, anti-Sjögren syndrome-associated antigen B
antibodies, anti-Sm antibodies, anti-Sc170 antibodies,
anti-dsDNA antibodies, anti-cardiolipin (anti-CL) anti-
bodies (Cogent Diagnostic, Edinburgh, UK), and anti-
U1RNP antibodies (Pharmacia and Upjohn, Freiburg,
Germany). Absorbances were measured by a Labsystems
Multiscan MS ELISA reader at 492 nm (Labsystems Oy,
Helsinki, Finland). The concentrations of samples were
determined using a standard curve obtained from the
optical densities of standards with known concentration.
Endothelial cell markers
Thrombomodulin levels were measured by ELISA using
commercial reagents according to the manufacturer's
instructions (Diagnostic Stago, Asnieres, France). All
assays were performed in duplicate. The intra-assay and
interassay coefficients of variation for all ELISA assays
were <5% and <10%, respectively.
The assessment of AECAs was performed on endothe-
lial cells from human umbilical cord veins, employing an
ELISA method, described previously in detail [11].
Laboratory examinations
The total cholesterol concentration was determined spec-
trophotometrically. Triglyceride and high-density lipo-
protein cholesterol (HDL-C) was measured with the
immune turbidimetric method. Low-density lipoprotein
cholesterol (LDL-C) was measured by homogenous,
enzymatic, colorimetric assay (Roche LDL-C plus 2nd
generation; Roche, Basel, Switzerland).
Apolipoprotein A1 (ApoA1) and apolipoprotein B were
assessed with the Orion Diagnostica kit (Orion Diagnos-
tica, Espoo, Finland), which employs an immune-neph-
elometric method. PON1 activity was measured
spectrophotometrically [13].
Endothelium-dependent (flow-mediated) and 
endothelium-independent (nitrate-mediated) vasodilation
Endothelium-dependent vasodilation was assessed with a
7.5-MHz linear array transducer (Hewlett-Packard Sonos
5500; Soma Technology Inc., Bloomfield, CT, USA) by
scanning the brachial artery in longitudinal sections, as
published previously [28]. Endothelial function testing
was performed by the same person (HD) and the evalua-
tion was carried out offline by a digital software tech-
nique (AVITA; Gtech Information Systems, Naperville,
IL, USA), as described previously in detail [29].
The inter-observer analysis found the variability on 20
patients to be 8.95%. The intra-observer analysis was per-
formed on 10 healthy individuals three times, with a 30-
minute interval between the analyses. The intra-observer
variability was 4.6%. We performed the variation coeffi-
cient for baseline diameter in 20 cases, and it was 0.86%;
the accuracy of the method is therefore appropriate
according to the international recommendation [30].
Carotid duplex ultrasound investigations; measurement of 
carotid artery intima-media thickness
Ultrasound examinations were performed immediately
after bloodsampling with the color-coded Hewlett Pack-
ard SONOS 5500 (Soma Technology Inc.) carotid duplex
equipment with a 7.5 MHz linear transducer. The investi-
gation included longitudinal and transverse examination-
sof the carotid arteries. Measurements of IMT were
performed at about 10 mm proximalto the carotid bulb,
or at 20 mm proximal to the flow divider. The IMTwas
measured as the distance between the leading edge of the
first echogenicline (lumen-intima interface) and the sec-
ond echogenic line(upper layer of the adventitia) in the
far (deeper) artery wall. All measurements were per-
formed at the end of the heart cycle, when the transduc-
erwas in the mediolateral direction [31]. Offline analysis
was performed by digital video images (AVITA; Gtech
Information Systems). Measurements were performedin
both carotid arteries and the larger of the two values was
used for analysis.
Statistical analysis
Normality of continuous variables was evaluated by the
Shapiro-Wilk test. As most variables were not normally
distributed, the Mann-Whitney test was used to compare
controls and MCTD patients. Factors that differed signif-Soltesz et al. Arthritis Research & Therapy 2010, 12:R78
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icantly between patients and controls in univariate tests
were entered in a general linear model to test whether
these factors are independent predictors of FMD, nitrate-
mediated dilation (NMD) and IMT. Statistica for Win-
dows (StatSoft, Tulsa, OK, USA) was used for data analy-
sis. Correlations were determined using Spearman
correlation coefficient. Statistical significance was
assumed when P < 0.05.
Results
In the patient group the mean ± standard deviation age at
the time of investigation was 50.2 ± 10.0 years (range: 17
to 69 years) and the disease duration was 9.56 ± 6.8 years
(range: 3 to 26 years). Patients with MCTD and the con-
trol group were similar with regards to age, systolic and
diastolic blood pressures, triglyceride, LDL-C, HDL-C, as
well as BMI (Table 1). The total cholesterol (P < 0.047),
the PON1 activity (P  < 0.001) and ApoA1 levels (P  <
0.001) were significantly lower in MCTD patients than in
the controls, while there was no difference in apolipopro-
tein B concentrations between patients with MCTD and
controls (P  = 0.693). The ApoA1 and PON1 activities
were lower in the MCTD/CVD+  and MCTD/CVD-
patient groups compared with controls. The ESR and hs-
CRP levels were significantly higher in patients with
MCTD and in the MCTD/CVD+  and MCTD/CVD-
groups compared with healthy controls.
The involvement of various organs is summarized in
Table 2. The presence of Raynaud's phenomenon (P  <
0.006), PAH (P = 0.0141), and secondary antiphospho-
lipid syndrome (P = 0.015) were significantly more fre-
quent in MCTD/CVD+ patients than in the MCTD/CVD-
patient group.
Concerning autoantibody profiles, all of the patients
were positive for antinuclear antibodies and anti-U1RNP
antibodies, 19 patients (38%) had anti-CL antibodies (IgG
or IgM anti-CL antibodies), and 22 patients (44%) were
positive for AECAs. The frequency of anti-CL-positive
and AECA-positive patients was significantly higher in
the MCTD/CVD+ group (anti-CL, P = 0.0195; AECA, P <
0.001).
The ratio of patients taking CS at the time of the study,
the cumulative median dose of CS, and other medications
are also presented in Table 2.
Raynaud's phenomenon was detected in 39 out of 50
patients with MCTD. In the MCTD/CVD+  group, 22
Table 1: Baseline characteristics of patients
Feature MCTDa Controls P value, MCTD 
vs. controls
MCTDb CVD+ MCTD CVD- P value, MCTD/
CVD+ vs. MCTD/
CVD-
n 50 38 23 27
Age at investigation (years) 50.2 ± 10.0 50.4 ± 10.3 0.936 50.1 ± 10.7 50.2 ± 9.5 0.99
Disease duration (years) 9.56 ± 6.8 (3 to 26) - - 10.3 ± 6.6 (3 to 26) 8.9 ± 6.9 (3 to 25) 0.481
SBP (mmHg) 137.4 ± 21.1 132.9 ± 19.6 0.367 144.7 ± 19.5 131.1 ± 20.6 0.037
DBP (mmHg) 90.9 ± 15.9 86.6 ± 15.3 0.215 88.5 ± 14.9 92.9 ± 16.8 0.299
BMI (kg/m2) 24.2 ± 1.3 23.2 ± 1.1 0.77 23.9 ± 1.1 24.81.9 0.383
Smoking
Former smokers 5 (10%) 5 (13.1) 0.7401 2 (8.6) 3 (11.1) 1.0
Nonsmokers 45 (90%) 33 (86.8%) 0.7401 21 (91.3) 24 (88.8) 1.0
Serum triglyceride (mmol/l) 1.611 ± 0.76 1.6 ± 0.79 0.755 1.5 ± 0.82 1.72 ± 0.70 0.3367
Total cholesterol (mmol/l) 5.94 ± 1.18 5.47 ± 1.03 0.047 5.8 ± 1.2 6.06 ± 1.13 0.108
HDL-C (mmol/l) 1.69 ± 0.5 1.68 ± 0.49 0.943 1.56 ± 0.48 1.8 ± 0.5 0.22
LDL-C (mmol/l) 3.62 ± 1.15 3.23 ± 0.88 0.148 3.52 ± 1.19 3.7 ± 1.12 0.333
ApoA1 (g/l) 1.31 ± 0.36 1.72 ± 0.47 <0.001 1.27 ± 0.3 1.33 ± 0.4 0.003
ApoB (g/l) 0.95 ± 0.31 0.91 ± 0.13 0.693 0.98 ± 0.38 0.89 ± 0.15 0.92
Paraoxonase-1 activity 113.6 ± 70.6 187.4 ± 68.3 <0.001 84.32 ± 69.66 138.7 ± 62.3 <0.001
hs-CRP (mg/l) 15.2 ± 9.62 1.44 ± 0.99 <0.001 22.1 ± 9.78 9.36 ± 3.96 <0.001
ESR (mm/hour) 20.2 ± 17.8 8.3 ± 3.9 <0.001 26.5 ± 17.6 14.4 ± 16.2 0.014
ApoA1, apolipoprotein A1; ApoB, apolipoprotein B; BMI, body mass index; CVD, cardiovascular disease; DBP, diastolic blood pressure; ESR: 
erythrocyte sedimentation rate; HDL-C, high-density lipoprotein-cholesterol; hs-CRP: high-sensitivity C-reactive protein; LDL-C, low-density 
lipoprotein-cholesterol; MCTD, mixed connective tissue disease; SBP, systolic blood pressure. aMann-Whitney U test. bKruskal-Wallis analysis of 
variance.Soltesz et al. Arthritis Research & Therapy 2010, 12:R78
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Table 2: Clinical symptoms of mixed connective tissue disease patients with and without cardiovascular diseases
MCTD manifestation MCTD (n = 50) MCTD/CVD+ (n = 23) MCTD/CVD- (n = 27) P valuea, CVD+ vs. CVD-
Disease duration (years) 9.56 ± 6.8 (3 to 26) 10.3 ± 6.6 (3 to 26) 8.9 ± 6.9 (3 to 25) 0.481
Polyarthritis 46 (92) 22 (95.6) 24 (88.8) 0.6123
Raynaud's phenomenon 39 (78) 22 (95.6) 17 (62.9) 0.006
Myositis 30 (60) 13 (56.5) 17 (62.9) 0.8621
Interstitial lung disease 40 (80) 19 (82.6) 21 (77.7) 0.7356
Photosensitivity 12 (24) 7 (30.4) 5 (18.5) 0.5077
Esophageal dysmotility 35 (70) 15 (65.2) 20 (74.0) 0.5480
Pulmonary arterial hypertension 12 (24) 9 (39.1) 3 (11.1) 0.0141
Lymphadenomegaly 13 (0.26) 5 (21.7) 8 (29.6) 0.7474
Serositis 19 (38) 11 (47.8) 8 (29.6) 0.2465
Secondary antiphospholipid syndrome 15 (30) 11 (47.8) 4 (14.8) 0.015
Previous venous thrombosis 13 (26.0) 9 (39.1) 4 (14.8) 0.618
Previous arterial occlusion 2 (4.0) 2 (8.69) 0
Anti-U1RNP (normal: <10 U/ml) 50 (100) 23 (100) 27 (100)
Anti-CL IgG/IgM (normal: <10 U/ml) 19 (38) 13 (56) 6 (22) 0.0195
AECA (normal: <5 U/ml) 22 (44) 15 (65) 7 (26) 0.001
SLAM (median) 5 5 4
SLAM (mean ± SD) 6.28 ± 4.04 6.95 ± 4.08 5.44 ± 4.0 0.199
SLAM (n) 18 (36) 11 (47.8) 7 (25.9) 0.1438
Medication
Nonsteroidal anti-inflammatory 
drugs
22 (44) 10 (43.4) 12 (44.4) 1.0
Last 2 months average dose of 
corticosteroids (mg/day)
3.36 ± 4.8 4.1 ± 3.4 3.1 ± 5.2 0.5306
Cumulative lifetime dose 
(prednisone equivalent)
14.21 (4 to 58.965) 13.0 (4 to 59.432) 15.2 (4 to 57.437) 0.674
Corticosteroids alone or 
combination (n)
28 (56) 11 (47.8) 17 (62.9) 0.3926
Patients currently 
corticosteroids alone n (%)
7 (14) 2 (8.6) 5 (18.5) 0.4295
Patients currently 
corticosteroids plus salazopyrine
10 (20) 5 (21.7) 5 (18.5) 1.0
Patients currently 
corticosteroids plus 
methotrexate
11 (22) 5 (21.7) 6 (22.2) 1.00
Cyclophosphamide treatment ever 37 (74) 21 (91.3) 16 (59.2) 0.0119
Antimalaric drugs treatment ever 39 (78) 19 (82.6) 20 (74.0) 0.515
Cyclosporin-A treatment ever 10 (20) 7 (30.4) 3 (11.1) 0.4804
Data presented as mean ± standard deviation, n (%) or median (25th to 75th percentile). AECA, anti-endothelial cell antibody; anti-CL, anti-
cardiolipin; anti-U1RNP, anti-U1 ribonucleoprotein; CVD, cardiovascular disease; MCTD, mixed connective tissue disease. The systemic lupus 
erythematosus disease activity measure (SLAM) is a measure of disease activity [24,25]. aFischer's exact test and Student t test.
patients had Raynaud's phenomenon. Among these, 10
patients' sera contained anti-CL IgG/IgM antibodies,
while 13 patients' sera were AECA-positive. An associa-
tion was found between Raynaud's phenomenon and
anti-CL IgG/IgM (P < 0.03), and between Raynaud's phe-
nomenon and the presence of AECA (P  < 0.02).
Percentage FMD, percentage NMD, IMT, autoantibodies 
and endothelial cell markers
Anti-U1RNP autoantibodies, anti-CL IgG/IgM type
autoantibodies, AECA and both endothelial cell markers
(TM and vWFAg) were significant increased in MCTDSoltesz et al. Arthritis Research & Therapy 2010, 12:R78
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patients versus controls and in the MCTD/CVD+ versus
MCTD/CVD- patient groups (Table 3).
Percentage FMD was significant lower in MCTD
patients compared with controls and in MCTD/CVD+
patients versus MCTD/CVD- patients (%FMD: MCTD,
4.7 ± 4.2% vs. controls, 8.7 ± 5.05%, P < 0.001; MCTD/
CVD+ vs. MCTD/CVD-, P < 0.0002). Percentage NMD
did not show a difference between MCTD and controls
and between the MCTD/CVD+  versus MCTD/CVD-
patient groups.
The IMT was significantly higher both in the MCTD
patients and in the MCTD/CVD+  vs. MCTD/CVD-
patients (IMT: MCTD, 0.64 ± 0.13 mm vs. controls, 0.53
± 0.14 mm, P < 0.001; MCTD/CVD+ vs. MCTD/CVD-, P
< 0.001).
Correlation between flow-and nitrate mediated 
vasodilation, IMT and other measured parameters in MCTD 
patients
A significant negative correlation was found between
percentage FMD and the disease duration (r = -0.6468, P
< 0.001), and between percentage FMD and systolic
blood pressure (r = -0.5423, P < 0.001) (Table 4). There
was a positive correlation between percentage FMD and
ApoA1 levels, and percentage FMD and PON1 activity
(ApoA1: r = 0.6203, P < 0.001; PON1 activity: r = 0.5957, P
< 0.001). Significant correlation was found between per-
centage FMD and AECA (r = -0.3075, P = 0.029), and
between percentage FMD and inflammatory parameters
such as the ESR (r = -0.4283, P < 0.001) and hs-CRP (r = -
0.4057, P = 0.003).
We found a negative correlation between SLAM score
and percentage FMD (r = -0.488, P < 0.001) (Figure 1).
NMD showed a negative association with hs-CRP (r = -
0.3207, P = 0.023) and the ESR (r = -0.3981, P < 0.001). No
other correlations were detected.
The IMT was significantly higher in MCTD patients
compared with controls (0.64 mm vs. 0.53 mm; P  <
0.001). The IMT was age dependent (r  = 0.5468, P  <
0.001), and showed an association with serum levels of
anti-U1RNP autoantibodies (P = 0.0025) and AECA (P =
0.0417), the endothelial cell markers TM (P <0.001) and
vWFAg (P < 0.001), and the ESR (P < 0.001) and hs-CRP
(P < 0.001).
In our patients we found a correlation between the ESR
and hs-CRP (r = 0.511, P < 0.001). In the MCTD/CVD+
group, 22 patients had Raynaud's phenomenon. Evalua-
tion of the relationship between MCTD patients with
Raynaud's phenomenon and FMD is presented in Table 5.
There was a significant association in MCTD patients
with and without Raynaud's phenomenon and FMD.
There was a negative association between FMD and
MCTD patients with Raynaud's phenomenon in the
CVD+ and CVD- groups.
Discussion
Cardiovascular diseases have recently been shown to be
the leading causes of morbidity and mortality in patients
with systemic autoimmune diseases. Some evidence
shows that in autoimmune disorders, such as SLE, rheu-
matoid arthritis and antiphospholipid syndrome, the sys-
temic inflammatory state itself predisposes to
atherosclerotic diseases [32-35].
MCTD is a systemic autoimmune disease, involving
many organs, while the most frequent, serious outcome is
the development of proliferative vascular lesions in the
lungs and other organs. Anti-U1RNP autoantibodies may
Table 3: Autoantibodies, endothelial cell parameters, FMD, NMD and IMT in MCTD patients with/without cardiovascular 
diseases
Feature MCTD (n = 50) Controls (n = 38) P value, 
MCTD vs. 
controlsa
MCTD/CVD+ (n = 23) MCTD/CVD- (n = 27) P value, MCTD/
CVD+ vs. 
MCTD/CVD-b
Anti-U1RNP (U/ml) 20.18 ± 14.6 8.02 ± 3.5 <0.001 30.3 ± 14.6 11.51 ± 7.28 <0.001
Anti-CL IgG/IgM (U/ml) 13.98 ± 12.2 6.06 ± 2.93 <0.001 21.02 ± 15.04 7.98 ± 2.95 <0.001
AECA (IU/ml) 50.1 ± 34.5 17.1 ± 8.48 <0.001 62.9 ± 26.3 39.1 ± 37.2 <0.001
Thrombomodulin (ng/ml) 12.2 ± 8.1 3.2 ± 1.3 <0.001 15.9 ± 5.2 9.0 ± 8.8 <0.001
vWFAg (%) 224.1 ± 115 89.4 ± 27.1 <0.001 311.5 ± 72.0 149.7 ± 90.0 <0.001
FMD (%) 4.76 ± 4.2 8.74 ± 5.05 <0.001 3.54 ± 2.9 5.81 ± 4.87 0.0002
NMD (%) 14.35 ± 6.67 17.16 ± 6.7 0.073 13.54 ± 6.06 15.03 ± 7.15 0.1283
IMT (mm) 0.64 ± 0.13 0.53 ± 0.14 <0.001 0.72 ± 0.11 0.57 ± 0.1 <0.001
AECA, anti-endothelial cell antibody; anti-CL, anti-cardiolipin; anti-U1RNP, anti-U1 ribonucleoprotein; CVD, cardiovascular disease; FMD, flow-
mediated dilation; IMT, intima-media thickness; MCTD, mixed connective tissue disease; NMD, nitrate-mediated dilation; vWFAg, von Willebrand 
factor antigen. aMCTD and controls, Mann-Whitney U test. bMCTD/CVD+ and MCTD/CVD-, analysis of variance test.Soltesz et al. Arthritis Research & Therapy 2010, 12:R78
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have an effect on endothelial cells; in some studies on
MCTD, however, the presence of antiphospholipid or
anti-endothelial antibodies, in addition to anti-RNP anti-
bodies, showed functional properties such as endothelial
cell activation - changing the phenotype of endothelial
cells, which become proinflammatory/procoagulant [36].
No previous studies, however, have been carried out to
assess the atherosclerotic risk factors in MCTD patients.
In our study population, we investigated the traditional
risk factors, in association with clinical symptoms and
autoantibodies, in MCTD patients with and without car-
diovascular events. This is the first study where endothe-
lial stiffness markers are measured, including FMD, NMD
and carotid IMT.
In our patients with MCTD, serum triglycerides, HDL-
C and LDL-C did not differ from healthy subjects, while
total cholesterol and the ApoA1 levels and serum PON1
activity within the liporpotein fraction were lower com-
pared with controls.
Decreased PON1 activity and mild elevation in hs-CRP
have drawn considerable interest, in relation to the devel-
opment of atherosclerosis that exemplifies a low-grade
chronic inflammatory process [37,38].
Decreased percentage FMD and increased IMT was
found in patients with MCTD. Our results indicated that
reduced FMD can clearly distinguish MCTD patients
from controls and, moreover , MCTD patients with and
without cardiovascular events. Decreased percentage
FMD showed a close correlation with the disease dura-
tion, systolic blood pressure, and inflamatory parameters
(hs-CRP and ESR).
High serum levels of hs-CRP have been shown to have a
close association with CVDs, representing a link between
chronic inflammation and hs-CRP with athrerosclerosis
[39]. A strong correlation was described between hs-CRP
and CVD events, when hs-CRP exceeded 3 mg/l [40]. In
our series, both hs-CRP and the ESR were elevated in
MCTD patients, escpecially in the MCTD/CVD+ group,
and percentage FMD showed a close negative correlation
with elevated ESR. These results may suggest that MCTD
patients have ongoing low-grade inflammation, and these
patients have an increased risk of severe CV events. A
close association between SLAM score and percentage
FMD shows that the disease activity involves endothelial
cell inflammation, causing endothelial cell dysfunction.
Serum concentration of anti-U1RNP autoantibodies
and levels of AECA were elevated in the patients'sera, and
both antibodies were higher in the MCTD/CVD+ patients
compared with the MCTD/CVD- group. Furthermore, we
showed that the markers of endothelial cell dysfunction,
vWFAg and soluble TM were higher in patients with
MCTD than in the healthy individuals.
In MCTD, high serum levels of vWFAg imply an acti-
vated state of endothelial cells and can play a pathogenic
Table 4: FMD, NMD and IMT in MCTD patients with/without cardiovascular disease and controls
%FMDa P value %NMDa P value IMTa P value
Age at investigation (years) -0.0221 0.878 -0.6700 0.001 0.5468 0.001
Disease duration (years) -0.6468 0.001 -0.1314 0.3628 0.1968 0.1706
Systolic blood pressure (mmHg) -0.5423 0.001 -0.1094 0.4492 0.2220 0.1211
Diastolic blood pressure (mmHg) 0.0946 0.5133 0.1005 0.4872 -0.1597 0.2676
Serum triglycerides (mmol/l) -0.3396 0.0158 0.2165 0.1309 -0.0411 0.7765
Serum cholesterol -0.0459 0.7514 0.0508 0.7255 -0.0209 0.8851
Apolipoprotein A1 (g/l) 0.6203 0.001 -0.0805 0.5782 -0.0248 0.8640
Apolipoprotein B (g/l) -0.3102 0.061 -0.0891 0.5997 0.0767 0.6517
Paraoxonase-1 activity 0.5957 0.001 0.1317 0.3619 -0.2789 0.0497
hs-CRP -0.4057 0.003 -0.3207 0.023 0.7164 0.001
ESR -0.4283 0.001 -0.3981 0.001 0.5467 0.001
Anti-U1RNP (U/ml) -0.0486 0.7371 -0.0694 0.6316 0.4182 0.0025
Anti-CL IgG (U/ml) -0.0717 0.6206 -0.0411 0.776 0.2236 0.1184
AECA (IU/ml) -0.3075 0.029 -0.2686 0.0592 0.2890 0.0417
Thrombomodulin (ng/ml) -0.0642 0.6577 -0.0165 0.9089 0.4823 0.00038
vWFAg (%) -0.0122 0.9329 -0.2692 0.058 0.5443 0.001
AECA, anti-endothelial cell antibody; anti-CL, anti-cardiolipin; anti-U1RNP, anti-U1 ribonucleoprotein; ESR, erythrocyte sedimentation rate; 
FMD, flow-mediated dilation; hs-CRP, high-sensitivity C-reactive protein; IMT, intima-media thickness; MCTD, mixed connective tissue 
disease; NMD, nitrate-mediated dilation; vWFAg, von Willebrand factor antigen. aSpearman rank correlation.Soltesz et al. Arthritis Research & Therapy 2010, 12:R78
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role in the development of atherothrombotic events [41].
Accordingly, in MCTD/CVD+ patients the soluble TM
levels were significant higher than in the MCTD/CVD-
group. TM is an endothelial cell activation marker, and its
shedding from the endothelial cell increases the risk of
cardiovascular and thrombotic events [12,42].
In patients with atherosclerotic diseases, soluble TM
was elevated and its level showed correlation with the
severity of coronary artery disease, and also an associa-
tion with worse outcome in survivals after acute myocar-
dial infarction [42]. Moreover, soluble TM is a good
marker of disease activity in SLE with lupus nephritis
[43].
vWFAg is a circulating glycoprotein, synthesized by
endothelial cells - and an increased serum concentration
of vWFAg has been shown to be a marker of endothelial
dysfunction in scleroderma, SLE and MCTD patients
with PAH [10,44].
In our patients with MCTD, percentage FMD strongly
correlated with disease duration, autoantibodies to anti-
U1RNP, AECA and anti-CL, and endothelial cell markers,
such as TM and vWFAg. These data indicate that the
reduced FMD is a good marker for monitoring cardiovas-
cular complications in MCTD.
One of the earliest stages of atherosclerosis is the
endothelial cell dysfunction [45]. Endothelium-depen-
dent FMD was described previously to be significantly
impaired in SLE [34], in rheumatoid arthritis [35], and in
antiphospholipid syndrome [29]. In our earlier study we
also found decreased FMD in patients with undifferenti-
ated connective tissue disease (UCTD), which is an early
stage of well-established connective tissue diseases [46].
Mosca and colleagues also investigated the vascular reac-
tivity in UCTD, and found that FMD and the response to
glyceryl trinitrate-mediated vasodilation were similar in
UCTD patients and healthy subjects. UCTD patients
were characterized, however, by having reduced response
to both acethylcholine and sodium nitroprusside in the
forearm microcirculation, indirectly indicating that
reduced endothelium-dependent vasodilation, a periph-
eral microvascular risk factor, signifies UCTD [47].
In the present study we found that FMD decreased and
the IMT was elevated in the MCTD/CVD+ patient group,
but there was no significant difference in NMD between
the MCTD/CVD+ and MCTD/CVD- patient groups. We
further described the presence of anti-CL antibodies and
AECA besides anti-U1RNP antibodies in MCTD; more-
over, serum levels of anti-U1RNP antibodies, anti-CL IgG
and AECA were higher in the MCTD/CVD+ group com-
pared with MCTD/CVD- patients.
We assume that AECA in MCTD patients could con-
tribute to endothelial cell dysfunction. AECAs are often
associated with phospholipid reactivity, present in SLE
and in primary antiphospholipid syndrome.
I n  c o n t r a s t  t o  t h e  d a t a  b y  L i m a  a n d  c o l l e a g u e s ,  w e
found that FMD showed a correlation with the activity
score [48]. Among the clinical symptoms, Raynaud's phe-
nomenon was more frequent in the MCTD/CVD+ group
- our data being similar to the findings of Aizer and col-
leagues [49]. Interestingly, anti-CL antibodies and
AECAs were more frequent in patients with Raynaud's
phenomenon, and these antibodies could provoke
Figure 1 Activity score and flow-mediated dilation in patients with mixed connective tissue disease. Y axis: flow-mediated dilation (%). X axis: 
systemic lupus activity measure score (number).
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endothelial cell damage. We assume that decreased FMD
may occur as a result of continuous endothelial cell acti-
vation and impairment.
The daily doses of CS and other immunosuppressive
treatment were similar in the CVD+ and CVD- groups.
Based on our data we believe that the vascular protection
i s  e s s e n t i a l  i n  p a t i e n t s  w i t h  M CT D ,  e s p e c i a l l y  i n  R a y -
naud's penomenon and PAH, and also aspirin and statin
therapy is important from the early stage of MCTD.
Carotid IMT was significant higher in MCTD patients
and showed an association with age, with disease dura-
tion and with traditional risk factors such as total choles-
terol levels, systolic blood pressure and diastolic blood
pressure. Ultrasound measurements of the carotid artery
IMT identify early structural vascular abnormalities. An
inverse correlation has been described previously
between the IMT and brachial arterial FMD. Endothelial
dysfunction showed a correlation with the IMT, suggest-
ing that the carotid IMT alone was a valid surrogate
marker for early atherosclerosis and had an important
predicting feature in cardiovascular events in the general
population [50-52].
Conclusions
We state that, besides traditional atherosclerotic factors,
autoantibodies play a crucial role in early atherosclerosis
in MCTD. We believe that anti-U1RNP antibodies and
AECA, as well as the upregulation of proinflammatory
cytokines associated with vascular endothelial cell dam-
age, may play a pivotal role in the early atherosclerotic
events in MCTD.
We assume that vWFAg and TM are the most impor-
tant markers of endothelial cell activation, and they
impair endothelial cell functions. Finally, we found a clear
d e c r e a s e  o f  p e r c e n t a g e  F M D  i n  M C T D  p a t i e n t s  w i t h
CVD, cerebrovascular events, and peripheral arterial dis-
ease.
Our findings support the idea that the immune-medi-
ated endothelial dysfunction, accelerated atherosclerosis
present in patients with MCTD. We assume that the utili-
zation of these serum markers and non-invasive cardio-
vascular measurements in the diagnosis of early
atherosclerosis in MCTD provides a sufficient back-
ground for the early introduction of endothelial protec-
tion (for example, aspirin, statin) in the future
management of the disease, before the development of
serious cardiovascular symptoms.
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